{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T20:22:17Z","timestamp":1787775737139,"version":"build-2784847793"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","license":[{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>To compare the long-term safety and efficacy of Adalimumab (ADA) and Infliximab (IFX) agents in biologic-naive patients with Ulcerative colitis (UC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The key focus was on specific outcomes such as the requirement of hospitalization due to UC, colectomy, steroid administration, and severe infections that led to the discontinuation of therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Anti-TNF treatment was initiated in 208 of the 475 patients with ulcerative colitis. The final study population consisted of 86 biologic-naive patients with UC, including 41 treated with IFX and 45 treated with ADA. No significant differences in treatment details, baseline Mayo scores, risk factors, or demographic features were observed. The ADA group displayed a significantly increased need for steroids (44.4%) compared to the IFX group (14.6%). The UC-associated hospitalization, colectomy, and serious infections were similar between the ADA and IFX groups. Similar outcomes were observed with IFX or ADA as monotherapy or in combination with immunomodulators. The survival analysis revealed IFX had a longer time to secondary loss of response compared to ADA, however, without statistical significance (72.5% versus 46.7%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.057).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Our results hint at the likelihood of IFX and ADA presenting similar clinical outcomes as first-time agents in UC. Nonetheless, the need for steroids with ADA should be taken into consideration.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/sjg.sjg_180_24","type":"journal-article","created":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T08:01:14Z","timestamp":1735545674000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Comparison of long-term outcomes of infliximab and adalimumab therapy in biologic-naive patients with ulcerative colitis"],"prefix":"10.4103","author":[{"given":"Muhammed B.","family":"Durak","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Faculty of Medicine, Hacettepe University, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yavuz","family":"Cagir","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Ankara City Hospital, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilhami","family":"Yuksel","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Ankara City Hospital, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,12,30]]},"reference":[{"key":"R1-20250109","first-page":"76","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"3532462","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med"},{"key":"R2-20250109","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1053\/j.gastro.2011.10.032","article-title":"Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis","volume":"142","author":"Sandborn","year":"2012","journal-title":"Gastroenterology"},{"key":"R3-20250109","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1517\/14656566.9.3.447","article-title":"Severe ulcerative colitis:Present medical treatment strategies","volume":"9","author":"Baudet","year":"2008","journal-title":"Expert Opin Pharmacother"},{"key":"R4-20250109","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.cgh.2006.09.033","article-title":"Response to corticosteroids in severe ulcerative colitis:A systematic review of the literature and a meta-regression","volume":"5","author":"Turner","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R5-20250109","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1111\/j.1365-2036.2011.04599.x","article-title":"Review article:Remission rates achievable by current therapies for inflammatory bowel disease","volume":"33","author":"Peyrin-Biroulet","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"R6-20250109","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1080\/14712598.2016.1203897","article-title":"Considerations, challenges and future of anti-TNF therapy in treating inflammatory bowel disease","volume":"16","author":"Pouillon","year":"2016","journal-title":"Expert Opin Biol Ther"},{"key":"R7-20250109","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1038\/ajg.2009.322","article-title":"Adverse events associated with common therapy regimens for moderate-to-severe Crohn's disease","volume":"104","author":"Marehbian","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"R8-20250109","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.cgh.2013.04.033","article-title":"Inflammatory bowel disease is associated with an increased risk of melanoma:A systematic review and meta-analysis","volume":"12","author":"Singh","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R9-20250109","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1002\/art.22579","article-title":"The effect of methotrexate and anti\u2013tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation","volume":"56","author":"Wolfe","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R10-20250109","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1097\/MIB.0000000000000754","article-title":"Comparative effectiveness of infliximab and adalimumab in Crohn's disease and ulcerative colitis","volume":"22","author":"Ananthakrishnan","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"R11-20250109","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/j.cgh.2016.11.024","article-title":"Comparison of infliximab and adalimumab in biologic-naive patients with ulcerative colitis:A nationwide danish cohort study","volume":"15","author":"Singh","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R12-20250109","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1056\/NEJM198712243172603","article-title":"Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study","volume":"317","author":"Schroeder","year":"1987","journal-title":"N Engl J Med"},{"key":"R13-20250109","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1136\/bmj.2.4947.1041","article-title":"Cortisone in ulcerative colitis;final report on a therapeutic trial","volume":"2","author":"Truelove","year":"1955","journal-title":"Br Med J"},{"key":"R14-20250109","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1136\/gut.2005.082909","article-title":"The Montreal classification of inflammatory bowel disease:Controversies, consensus, and implications","volume":"55","author":"Satsangi","year":"2006","journal-title":"Gut"},{"key":"R15-20250109","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.crohns.2012.09.003","article-title":"Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1:Definitions and diagnosis","volume":"6","author":"Dignass","year":"2012","journal-title":"J Crohns Colitis"},{"key":"R16-20250109","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/ecco-jcc\/jjx008","article-title":"Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1:Definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders","volume":"11","author":"Magro","year":"2017","journal-title":"J Crohns Colitis"},{"key":"R17-20250109","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1093\/ibd\/izy322","article-title":"Treatment persistence of infliximab versus adalimumab in ulcerative colitis:A 16-year single-center experience","volume":"25","author":"Pouillon","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"R18-20250109","article-title":"Comparative effectiveness and safety of infliximab and adalimumab in patients with ulcerative colitis","volume":"43994","author":"Singh","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"R19-20250109","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/apt.14449","article-title":"Systematic review with network meta-analysis:Comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis","volume":"47","author":"Bonovas","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"R20-20250109","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/apt.14422","article-title":"Systematic review with network meta-analysis:First- and second-line pharmacotherapy for moderate-severe ulcerative colitis","volume":"47","author":"Singh","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"R21-20250109","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/MIB.0000000000001025","article-title":"Factors associated with discontinuation of anti-TNF inhibitors among persons with IBD:A population-based analysis","volume":"23","author":"Targownik","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"R22-20250109","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1053\/j.gastro.2013.10.052","article-title":"Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis","volume":"146","author":"Panaccione","year":"2014","journal-title":"Gastroenterology"}],"container-title":["Saudi Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/sjg.sjg_180_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:40:58Z","timestamp":1787773258000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/sjg.sjg_180_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,30]]},"references-count":22,"URL":"https:\/\/doi.org\/10.4103\/sjg.sjg_180_24","relation":{},"ISSN":["1319-3767","1998-4049"],"issn-type":[{"value":"1319-3767","type":"print"},{"value":"1998-4049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,30]]},"assertion":[{"value":"2024-05-18","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-19","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}